Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case.

Literature DB >> 16715430

Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case.

Ryota Higuchi¹, Masakazu Yamamoto, Takashi Hatori, Koichi Shimizu, Kenichirou Imai, Ken Takasaki.

Abstract

Intrahepatic cholangiocarcinoma (ICC) with lymph node (LN) metastasis is generally associated with a poor prognosis. However, we treated ICC with LN metastasis successfully by surgery and postoperative immunotherapy in a 59-year-old woman. The immunotherapy consisted of CD3-activated T cells and tumor lysate- or peptide-pulsed dendritic cells. Pathological examination confirmed a diagnosis of moderately differentiated adenocarcinoma with LN metastasis and portal vein invasion. The patient has been alive without recurrence for 3 years 6 months since her operation.

Entities: Disease Species

Mesh：

Substances：
CD3 Complex

Year: 2006 PMID： 16715430 DOI： 10.1007/s00595-006-3201-1

Source DB: PubMed Journal: Surg Today ISSN： 0941-1291 Impact factor: 2.549

14 in total

1. Extended resection for intrahepatic cholangiocarcinoma in Japan.

Authors: M Yamamoto; K Takasaki; T Yoshikawa
Journal: J Hepatobiliary Pancreat Surg Date: 1999

2. Long-term survival of peripheral intrahepatic cholangiocarcinoma with metastasis to the para-aortic lymph nodes.

Authors: Y Murakami; T Yokoyama; Y Takesue; E Hiyama; Y Yokoyama; T Kanehiro; K Uemura; Y Matsuura
Journal: Surgery Date: 2000-01 Impact factor: 3.982

3. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

Authors: T Takayama; T Sekine; M Makuuchi; S Yamasaki; T Kosuge; J Yamamoto; K Shimada; M Sakamoto; S Hirohashi; Y Ohashi; T Kakizoe
Journal: Lancet Date: 2000-09-02 Impact factor: 79.321

4. Long-term survival after curative left hepatectomy for mucin-producing cholangiocarcinoma: report of a case.

Authors: Takahiro Tsuchikawa; Satoshi Kondo; Satoshi Hirano; Eiichi Tanaka; Yoshiyasu Anbo; Toshiaki Morikawa; Shunichi Okushiba; Noriyuki Otsuka; Tomoo Itoh; Hiroyuki Katoh
Journal: Surg Today Date: 2005 Impact factor: 2.549

5. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

Authors: J D Geiger; R J Hutchinson; L F Hohenkirk; E A McKenna; G A Yanik; J E Levine; A E Chang; T M Braun; J J Mulé
Journal: Cancer Res Date: 2001-12-01 Impact factor: 12.701

6. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma.

Authors: Naoki Matsumura; Masakazu Yamamoto; Atsushi Aruga; Ken Takasaki; Masayuki Nakano
Journal: Cancer Date: 2002-03-15 Impact factor: 6.860

7. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

Authors: Alfred E Chang; Bruce G Redman; Joel R Whitfield; Brian J Nickoloff; Thomas M Braun; Peter P Lee; James D Geiger; James J Mulé
Journal: Clin Cancer Res Date: 2002-04 Impact factor: 12.531

8. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells.

Authors: J Geiger; R Hutchinson; L Hohenkirk; E McKenna; A Chang; J Mulé
Journal: Lancet Date: 2000-09-30 Impact factor: 79.321

9. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.

Authors: K Shimizu; E K Thomas; M Giedlin; J J Mulé
Journal: Cancer Res Date: 2001-03-15 Impact factor: 12.701

10. Report of the 15th follow-up survey of primary liver cancer.

Authors: Iwao Ikai; Yuji Itai; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Kobayashi; Yasuni Nakanuma; Shunji Futagawa; Masatoshi Makuuchi; Yoshio Yamaoka
Journal: Hepatol Res Date: 2004-01 Impact factor: 4.288

13 in total

1. Intrahepatic recurrence after surgery in patients with intrahepatic cholangiocarcinoma.

Authors: Masakazu Yamamoto; Shun-ichi Ariizumi
Journal: J Gastroenterol Date: 2006-09 Impact factor: 7.527

Review 2. The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics.

Authors: Yuji Morine; Mitsuo Shimada
Journal: J Gastroenterol Date: 2015-04-02 Impact factor: 7.527

Review 3. Immunotherapeutic Approaches to Biliary Cancer.

Authors: Urvi A Shah; Amara G Nandikolla; Lakshmi Rajdev
Journal: Curr Treat Options Oncol Date: 2017-07

4. Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma.

Authors: Georgi Atanasov; Corinna Dietel; Linda Feldbrügge; Christian Benzing; Felix Krenzien; Andreas Brandl; Elli Mann; Julianna Paulina Englisch; Katrin Schierle; Simon C Robson; Katrin Splith; Mehmet Haluk Morgul; Anja Reutzel-Selke; Sven Jonas; Andreas Pascher; Marcus Bahra; Johann Pratschke; Moritz Schmelzle
Journal: Oncoimmunology Date: 2017-06-28 Impact factor: 8.110

Review 10. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors: Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal: Adv Cancer Res Date: 2020-12-09 Impact factor: 6.242